Laboratory Corporation of America Holdings Valuation
Is LH * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of LH * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: LH * (MX$3524.01) is trading below our estimate of fair value (MX$8022.66)
Significantly Below Fair Value: LH * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LH *?
Other financial metrics that can be useful for relative valuation.
What is LH *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$16.73b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.8x |
Enterprise Value/EBITDA | 14x |
PEG Ratio | 2x |
Price to Earnings Ratio vs Peers
How does LH *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 25x | ||
FRE Fresenius SE KGaA | 43.4x | 22.6% | €15.3b |
DGX Quest Diagnostics | 17.7x | 8.9% | US$14.9b |
DVA DaVita | 16.9x | 6.4% | US$11.7b |
FME Fresenius Medical Care | 22x | 20.7% | €11.0b |
LH * Laboratory Corporation of America Holdings | 41.9x | 21.0% | Mex$16.7b |
Price-To-Earnings vs Peers: LH * is expensive based on its Price-To-Earnings Ratio (41.9x) compared to the peer average (25x).
Price to Earnings Ratio vs Industry
How does LH *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: LH * is expensive based on its Price-To-Earnings Ratio (41.9x) compared to the Global Healthcare industry average (21.4x).
Price to Earnings Ratio vs Fair Ratio
What is LH *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 41.9x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate LH *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.